STAT Reports

Good bacteria: The microbiome, its vast therapeutic potential, and the challenges ahead

$499.00

Good bacteria: The microbiome, its vast therapeutic potential, and the challenges ahead
License Type:

Published: April 2021

In the late 1950s a radical idea was born: What if a patients’ gastrointestinal inflammation could be cured by implanting a healthier gut? The result, now known as a fecal microbiota transplant, is the foundation of the microbiome industry. While the field is still in its commercial infancy, it is showing promise — companies like Seres Therapeutics, Rebiotix, and Finch Therapeutics are already presenting mid- and late-stage clinical trial data for their live biotherapeutic products, and several others have successfully completed early-stage human studies.


This report examines the science behind this nascent industry, fleshing out what we know about the ecology of the human microbiome and the various interventions scientists are studying to help keep or make it healthy. It also looks at the vast array of conditions that microbiome companies are hoping to treat, and the challenges that these biotechs face in research, manufacturing, regulation and ultimately bringing these treatments to the clinic.

How it works

Add this report to your cart, and then complete the checkout process. Once you have, you'll receive an email with the link to download the full report file. This report is digital-only, so you will not receive a printout.

Preview

Take a peek at what's included in this report.